ClinicalTrials.gg
CompletedNCT01715831RITACTUpdated Jun 12, 2017Results posted

A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488

A Phase 4 interventional study of DMARDs and Tocilizumab in Arthritis, Rheumatoid, sponsored by Hoffmann-La Roche. Completed at 9 sites in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
93rd of 110
26 · median 97
Started
2013
with 8 others
Phase 4
32 of 110
2 open now
Registered
68th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 93rd largest by enrollment, is one of 9 that started in 2013, is one of 32 in phase 4, and was the 68th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label, single-arm extension study will evaluate the long-term safety of tocilizumab (RoActemra/Actemra) in participants with RA. Participants who have completed the MA21488 (NCT00810199) core study and the ML21530 (NCT00754572) study and who could benefit from the study drug, according to the opinion of the investigator, will receive 8 milligrams per kilogram (mg/kg) of intravenous (IV) tocilizumab every 4 weeks. The anticipated time on study treatment is 104 weeks.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who have completed their last visit in the core studies ML21530 and MA21488 and that might benefit from treatment using the study drug according to the investigator's evaluation
  • Absence of an AE or current or recent laboratory finding that would prevent the use of the 8 mg/kg dose of the tocilizumab
  • Receiving outpatient treatment
  • For women who are not and are not surgically sterile: agreement to use at least one adequate method of

Exclusion criteria

Exclusion Criteria:

  • Participants who have prematurely discontinued the core studies ML21530 and MA21488 for any reason
  • MA21488 study participants who remained untreated with tocilizumab after it's discontinuation according to the treatment-free remission criteria of MA21488 study
  • Immunization with a live/attenuated vaccine since the last administration of the study drug in the core studies ML21530 and ML21488
  • Diagnosis after the last visit of the study ML21530 or after the last visit of the study MA21488 of a rheumatic disease other than RA, including systemic erythematous lupus (SEL), mixed connective tissue disease (MCTD), scleroderma and polymyositis, or a significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjogren's Syndrome and/or nodulosis with RA are allowed
  • Diagnosis after the last visit of the core study ML21530 or of the study MA21488 of an inflammatory joint disease other than RA
  • Abnormal laboratory parameters at the baseline
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Evidences of a concomitant, serious and uncontrolled illness
  • Known active condition or a history of recurrent infections by bacteria, viruses, fungi, mycobacteria or other agents
  • Evidence of an active malignant disease, diagnosed in the last 10 years or breast cancer diagnosed in the last 20 years
  • Uncontrolled disease status, such as asthma or inflammatory bowel disease in which acute crises are usually treated with oral or parenteral
  • Current hepatic disease, as determined by the investigator
  • Active tuberculosis (TB) requiring treatment in the previous three years. Participants should be screened for latent TB according to local practice guidelines and should not be admitted into the study if latent TB is detected. Participants must not present any evidence of active TB infection at the enrollment. Participants treated for tuberculosis without recurrence in three years are allowed
  • History of alcohol, drugs or chemical abuse since the inclusion in the core studies ML21530 and MA21488
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab 8 mg/kg IV infusion every 4 weeks for a total of 104 weeks. The maximum single dose administered to any participant will be of 800 mg of tocilizumab. Participants may also receive disease-modifying anti-rheumatic drugs (DMARDs) in addition to the tocilizumab treatment in any visit, at the investigator discretion, according to the local prescription information and participant's tolerance.

    Drug: DMARDs · Drug: Tocilizumab

Interventions

  • DrugDMARDs

    DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.

  • Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks

    Also known as: RoActemra; Actemra

06

What researchers measure

Primary outcomes

  1. Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs)

    An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; significant medical event, according to the investigator discretion (e.g., may represent a risk to the participant or may require medical/surgical intervention to prevent one of the outcomes mentioned above).

    Time frame: From Baseline up to approximately 2 years

  2. Number of Participants With AEs Leading to Dose Modification or Study Discontinuation

    Time frame: From Baseline up to approximately 2 years

  3. Number of Participants With AEs of Special Interest

    Adverse events of special interest included following events: Infections (including opportunistic infections); myocardial infarction / acute coronary syndrome; gastrointestinal (GI) perforations and related events; malignancies; anaphylaxis/hypersensitivity reactions; demyelinating disorders; stroke; hemorrhagic events; and hepatic events. Overall number of participants who experienced any of these AEs of special interest was reported.

    Time frame: From Baseline up to approximately 2 years

Secondary outcomes

  1. Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

    DAS28 score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), participant's global assessment of disease activity (general health \[GH\]) using visual analog scale (VAS), 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28 = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and follow-up (FU) Visit 1 (Week 108), FU Visit 2 (Week 116)

  2. Tender Joint Count (TJC)

    An assessment of 28 joints was conducted for tenderness. Joints were assessed and classified as tender/not tender by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for tenderness.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  3. Swollen Joint Count (SJC)

    An assessment of 28 joints was conducted for swelling. Joints were assessed and classified as swollen/not swollen by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for swelling.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  4. Global Evaluation of Disease Activity by the Participant Using VAS Score

    Participant's global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The participant marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  5. Global Evaluation of Disease Activity by the Physician Using VAS Score

    Physician global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The physician marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  6. Participant's Pain Assessment Using VAS Score

    Participant's pain assessment was made on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "no pain" and 100 mm (right end of the line) as "unbearable pain". The participant marked the line according to their assessment and the distance from the left edge was measured.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  7. Health Assessment Questionnaire - Disability Index (HAQ-DI) Score

    The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/personal care, ability to stand-up, eating, walking, hygiene, reaching, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents 'no disability' and 3 represents 'very severe, high-dependency disability'.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  8. Health Assessment Questionnaire (HAQ) Pain VAS Score

    The HAQ pain VAS is a measure of pain on a continuous 100 mm scale. Participants were asked to indicate how much pain they had in the past week as a result of their illness on a horizontal line from 0 (no pain) to 100 mm (severe pain).

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  9. C-Reactive Protein (CRP) Level

    CRP is an acute phase reactant and is a measure of inflammation.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

  10. ESR Level

    ESR is an acute phase reactant and is a measure of inflammation.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)

07

Results

Posted Jun 12, 2017

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab
Started26
Completed25
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs)

An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; significant medical event, according to the investigator discretion (e.g., may represent a risk to the participant or may require medical/surgical intervention to prevent one of the outcomes mentioned above).

Time frame:
From Baseline up to approximately 2 years
Reported as:
Number · participants
Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (NSAEs)
participantsTocilizumab
SAEs4
NSAEs24
PrimaryNumber of Participants With AEs Leading to Dose Modification or Study Discontinuation
Time frame:
From Baseline up to approximately 2 years
Reported as:
Number · participants
Number of Participants With AEs Leading to Dose Modification or Study Discontinuation
participantsTocilizumab
AEs leading to dose modification7
AEs leading to study discontinuation1
PrimaryNumber of Participants With AEs of Special Interest

Adverse events of special interest included following events: Infections (including opportunistic infections); myocardial infarction / acute coronary syndrome; gastrointestinal (GI) perforations and related events; malignancies; anaphylaxis/hypersensitivity reactions; demyelinating disorders; stroke; hemorrhagic events; and hepatic events. Overall number of participants who experienced any of these AEs of special interest was reported.

Time frame:
From Baseline up to approximately 2 years
Reported as:
Number · participants
Number of Participants With AEs of Special Interest
participantsTocilizumab
Number of Participants With AEs of Special Interest0
SecondaryDisease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)

DAS28 score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), participant's global assessment of disease activity (general health \[GH\]) using visual analog scale (VAS), 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (erythrocyte sedimentation rate \[ESR\] in millimeters per hour \[mm/hr\]) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28 = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and follow-up (FU) Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · units on a scale
Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR)
units on a scaleTocilizumab
Baseline (n=26)2.76 ± 1.19
Week 12 (n=24)2.23 ± 0.86
Week 24 (n=25)2.43 ± 1.01
Week 36 (n=25)2.04 ± 0.85
Week 48 (n=21)2.32 ± 1.23
Week 56 (n=24)1.82 ± 0.55
Week 68 (n=23)2.21 ± 0.84
Week 80 (n=24)2.06 ± 0.64
Week 92 (n=24)2.23 ± 0.96
Week 104 (n=25)1.92 ± 0.93
FU Visit 1 (n=13)1.70 ± 1.02
FU Visit 2 (n=24)3.21 ± 1.35
SecondaryTender Joint Count (TJC)

An assessment of 28 joints was conducted for tenderness. Joints were assessed and classified as tender/not tender by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for tenderness.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · tender joints
Tender Joint Count (TJC)
tender jointsTocilizumab
Baseline (n=26)2.8 ± 3.6
Week 12 (n=24)1.8 ± 2.3
Week 24 (n=25)2.0 ± 3.6
Week 36 (n=25)1.9 ± 2.5
Week 48 (n=21)2.8 ± 3.8
Week 56 (n=24)1.1 ± 1.2
Week 68 (n=23)2.0 ± 2.6
Week 80 (n=24)1.6 ± 2.0
Week 92 (n=24)1.5 ± 1.7
Week 104 (n=25)1.5 ± 1.8
FU Visit 1 (n=13)1.8 ± 3.7
FU Visit 2 (n=24)2.8 ± 4.7
SecondarySwollen Joint Count (SJC)

An assessment of 28 joints was conducted for swelling. Joints were assessed and classified as swollen/not swollen by pressure and joint manipulation after a physical examination. Artificial joints, arthrodesis or fused joints were not taken into consideration for swelling.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · swollen joints
Swollen Joint Count (SJC)
swollen jointsTocilizumab
Baseline (n=26)1.4 ± 2.0
Week 12 (n=24)1.0 ± 2.0
Week 24 (n=25)0.6 ± 1.2
Week 36 (n=25)0.9 ± 1.0
Week 48 (n=21)1.4 ± 2.5
Week 56 (n=24)0.8 ± 1.8
Week 68 (n=23)0.9 ± 1.5
Week 80 (n=24)0.4 ± 0.8
Week 92 (n=24)0.8 ± 1.2
Week 104 (n=25)0.6 ± 1.3
FU Visit 1 (n=13)0.2 ± 0.4
FU Visit 2 (n=24)1.5 ± 2.2
SecondaryGlobal Evaluation of Disease Activity by the Participant Using VAS Score

Participant's global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The participant marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · mm
Global Evaluation of Disease Activity by the Participant Using VAS Score
mmTocilizumab
Baseline (n=26)35.2 ± 25.3
Week 12 (n=26)36.4 ± 26.4
Week 24 (n=26)38.4 ± 27.2
Week 36 (n=25)31.8 ± 25.0
Week 48 (n=23)32.8 ± 28.8
Week 56 (n=25)30.6 ± 22.7
Week 68 (n=24)32.4 ± 24.6
Week 80 (n=24)36.1 ± 26.2
Week 92 (n=25)36.2 ± 25.5
Week 104 (n=25)33.4 ± 25.2
FU Visit 1 (n=15)37.1 ± 28.0
FU Visit 2 (n=25)42.6 ± 29.9
SecondaryGlobal Evaluation of Disease Activity by the Physician Using VAS Score

Physician global assessment of disease activity was measured on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "inactive disease" (free of symptoms and without symptoms of arthritis) and 100 mm (right end of the line) as "disease maximum activity" (maximum activity of arthritis). The physician marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · mm
Global Evaluation of Disease Activity by the Physician Using VAS Score
mmTocilizumab
Baseline (n=26)20.6 ± 18.7
Week 12 (n=26)11.4 ± 14.1
Week 24 (n=26)13.8 ± 14.7
Week 36 (n=25)13.1 ± 10.4
Week 48 (n=23)9.1 ± 11.3
Week 56 (n=25)13.0 ± 13.3
Week 68 (n=24)11.6 ± 11.9
Week 80 (n=24)11.3 ± 11.2
Week 92 (n=25)13.7 ± 11.7
Week 104 (n=25)10.0 ± 9.7
FU Visit 1 (n=15)11.7 ± 11.5
FU Visit 2 (n=25)15.3 ± 18.4
SecondaryParticipant's Pain Assessment Using VAS Score

Participant's pain assessment was made on a horizontal 0-100 mm VAS, with 0 mm (left end of the line) described as "no pain" and 100 mm (right end of the line) as "unbearable pain". The participant marked the line according to their assessment and the distance from the left edge was measured.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · mm
Participant's Pain Assessment Using VAS Score
mmTocilizumab
Baseline (n=26)31.9 ± 21.7
Week 12 (n=26)29.0 ± 25.1
Week 24 (n=26)33.7 ± 25.4
Week 36 (n=25)28.6 ± 21.5
Week 48 (n=23)27.8 ± 25.2
Week 56 (n=25)27.4 ± 23.1
Week 68 (n=24)27.8 ± 23.1
Week 80 (n=24)31.9 ± 24.3
Week 92 (n=25)29.5 ± 22.7
Week 104 (n=25)28.6 ± 22.6
FU Visit 1 (n=15)28.9 ± 25.8
FU Visit 2 (n=25)42.6 ± 30.1
SecondaryHealth Assessment Questionnaire - Disability Index (HAQ-DI) Score

The Stanford HAQ-DI is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/personal care, ability to stand-up, eating, walking, hygiene, reaching, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents 'no disability' and 3 represents 'very severe, high-dependency disability'.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · units on a scale
Health Assessment Questionnaire - Disability Index (HAQ-DI) Score
units on a scaleTocilizumab
Baseline (n=26)0.68 ± 0.61
Week 12 (n=26)0.49 ± 0.43
Week 24 (n=26)0.49 ± 0.38
Week 36 (n=25)0.49 ± 0.45
Week 48 (n=23)0.48 ± 0.49
Week 56 (n=24)0.53 ± 0.60
Week 68 (n=24)0.52 ± 0.47
Week 80 (n=24)0.53 ± 0.48
Week 92 (n=23)0.43 ± 0.44
Week 104 (n=24)0.48 ± 0.50
FU Visit 1 (n=15)0.56 ± 0.42
FU Visit 2 (n=23)0.63 ± 0.59
SecondaryHealth Assessment Questionnaire (HAQ) Pain VAS Score

The HAQ pain VAS is a measure of pain on a continuous 100 mm scale. Participants were asked to indicate how much pain they had in the past week as a result of their illness on a horizontal line from 0 (no pain) to 100 mm (severe pain).

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · mm
Health Assessment Questionnaire (HAQ) Pain VAS Score
mmTocilizumab
Baseline (n=26)31.9 ± 22.6
Week 12 (n=26)30.8 ± 24.5
Week 24 (n=26)37.8 ± 26.3
Week 36 (n=25)30.1 ± 23.4
Week 48 (n=23)32.7 ± 29.4
Week 56 (n=24)31.3 ± 24.0
Week 68 (n=24)32.9 ± 25.1
Week 80 (n=24)34.4 ± 27.2
Week 92 (n=23)38.2 ± 30.3
Week 104 (n=24)29.0 ± 23.9
FU Visit 1 (n=15)30.9 ± 24.8
FU Visit 2 (n=22)43.3 ± 32.8
SecondaryC-Reactive Protein (CRP) Level

CRP is an acute phase reactant and is a measure of inflammation.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · milligrams per deciliter (mg/dL)
C-Reactive Protein (CRP) Level
milligrams per deciliter (mg/dL)Tocilizumab
Baseline (n=24)0.51 ± 0.91
Week 12 (n=26)3.13 ± 6.17
Week 24 (n=25)1.08 ± 1.58
Week 36 (n=25)2.58 ± 3.00
Week 48 (n=21)0.21 ± 0.27
Week 56 (n=24)0.41 ± 0.92
Week 68 (n=24)0.43 ± 0.74
Week 80 (n=24)0.64 ± 1.91
Week 92 (n=23)1.86 ± 7.11
Week 104 (n=25)0.12 ± 0.16
FU Visit 1 (n=13)0.10 ± 0.11
FU Visit 2 (n=24)1.46 ± 5.05
SecondaryESR Level

ESR is an acute phase reactant and is a measure of inflammation.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, 104, and FU Visit 1 (Week 108), FU Visit 2 (Week 116)
Reported as:
Mean · mm/hr
ESR Level
mm/hrTocilizumab
Baseline (n=26)9.8 ± 10.2
Week 12 (n=24)4.9 ± 3.1
Week 24 (n=25)8.5 ± 7.6
Week 36 (n=25)4.6 ± 3.2
Week 48 (n=21)5.1 ± 4.7
Week 56 (n=24)4.9 ± 5.3
Week 68 (n=23)6.7 ± 7.2
Week 80 (n=24)6.4 ± 9.1
Week 92 (n=24)7.5 ± 9.2
Week 104 (n=25)5.5 ± 6.3
FU Visit 1 (n=13)4.8 ± 5.0
FU Visit 2 (n=24)21.9 ± 29.7

Adverse events

Collected over From Baseline up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—4/26 (15.4%)24/26 (92.3%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
Ischaemic strokeNervous system disorders1/26
Total lung capacity decreasedInvestigations1/26
Lung disorderRespiratory, thoracic and mediastinal disorders1/26
Corneal perforationInjury, poisoning and procedural complications1/26
DiverticulitisGastrointestinal disorders1/26
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTocilizumab
Respiratory tract infection NOSInfections and infestations12/26
Musculoskeletal painMetabolism and nutrition disorders8/26
Urinary tract infectionInfections and infestations7/26
DyslipidaemiaMetabolism and nutrition disorders6/26
HeadacheNervous system disorders5/26
DyspepsiaGastrointestinal disorders4/26
TonsillitisInfections and infestations4/26
PneumoniaRespiratory, thoracic and mediastinal disorders4/26
HypercholesterolemiaMetabolism and nutrition disorders3/26
AnxietyPsychiatric disorders3/26

Baseline characteristics

Intention to treat (ITT) population included all participants who received at least one dose of tocilizumab during the study.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean56.0 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female25
Male1
08

Study locations

9 sites
  • Santa Casa de Misericordia de Salvador; Reumatologia
    Salvador, BA 40050-410, Brazil
  • Hospital Universitario Cassiano Antonio Moraes - UFES; Reumatologia
    Vitoria, ES 29043-910, Brazil
  • Centro Mineiro de Pesquisa - CMIP
    Juiz de Fora, MG 36036-330, Brazil
  • Hospital das Clinicas - UNICAMP
    Campinas, SP 13083-888, Brazil
  • Hospital de Base de Sao Jose do Rio Preto
    Sao Jose do Rio Preto, SP 15090-000, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP; Reumatologia
    Sao Paulo, SP 04026-000, Brazil
  • Hospital Abreu Sodre - AACD;Reumatologia
    Sao Paulo, SP 04027-000, Brazil
  • Hospital Estadual do Servidor Publico; Reumatologia
    Sao Paulo, SP 04039-004, Brazil
  • Centro Paulista de Investigacao Clinica - CEPIC
    Sao Paulo, SP 04266-010, Brazil
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2013 to primary completion in Jun 2016, 40 months.

Results were first posted in Jun 2017, 1 year after primary completion.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 40 months is above that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2012
First posted
Oct 29, 2012
StartActual
Jan 15, 2013
Primary completionActual
Jun 6, 2016
CompletionActual
Jun 6, 2016
Results first posted
Jun 12, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01715831
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 29, 2012
Start date
Jan 15, 2013
Primary completion
Jun 6, 2016
Completion
Jun 6, 2016
Results posted
Jun 12, 2017
Last update
Jun 12, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion